The specter of generic competition has long loomed around copyright’s famous drug, Viagra, triggering questions about the prospects of related pharmaceutical stakes. While first times saw substantial profits, the patent end has opened the door for discounted copies, potentially reducing profitability and posing a genuine danger for shareholders s